研究论文

无过渡金属参与的“一锅法”合成咔啉及其衍生物的新方法

  • 谢桂玲 a, b, ,
  • Sudhakar Reddy Mopuri b, ,
  • 李杰 b ,
  • 杨元勇 a ,
  • 陈铁根 , b, c, *
展开
  • a 贵州医科大学药学院 中药功效成分发掘与利用全国重点实验室 贵阳 550000
  • b 中科中山药物创新研究院 广东中山 528400
  • c 中国科学院上海药物研究所 上海 201203

共同第一作者.

收稿日期: 2025-05-06

  修回日期: 2025-05-21

  网络出版日期: 2025-06-12

基金资助

国家自然科学基金(22371303)

中山市科技局(2021B2014)

中山市科技局(CXTD2022013)

上海市科委“启明星”计划(21QA1411000)

One-Pot Transition-Metal-Free Synthesis of Carboline Derivatives via Dual C—N Bond Formation

  • Guiling Xie a, b ,
  • Sudhakar Reddy Mopuri b ,
  • Jie Li b ,
  • Yuanyong Yang a ,
  • Tie-Gen Chen , b, c, *
Expand
  • a State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 550000
  • b Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong 528400
  • c Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203

The authors contributed equally to this work.

Received date: 2025-05-06

  Revised date: 2025-05-21

  Online published: 2025-06-12

Supported by

National Natural Science Foundation of China(22371303)

Zhongshan Municipal Bureau of Science and Technology(2021B2014)

Zhongshan Municipal Bureau of Science and Technology(CXTD2022013)

Shanghai Rising-Star Program(21QA1411000)

摘要

报道了一种以二卤代联芳基吡啶化合物和伯胺为起始原料, 通过构建两个C—N键合成一系列α-、β-、γ-、δ-咔啉及其衍生物的方法. 反应在叔丁醇锂(t-BuOLi)或碳酸铯(Cs2CO3)存在下进行, 无需使用任何金属和氧化剂, 具有良好的底物适用性. 该方法可以实现克级规模的制备以及有机材料2,6-CbPy的合成,并进行产物转化.

本文引用格式

谢桂玲 , Sudhakar Reddy Mopuri , 李杰 , 杨元勇 , 陈铁根 . 无过渡金属参与的“一锅法”合成咔啉及其衍生物的新方法[J]. 有机化学, 2025 , 45(10) : 3824 -3837 . DOI: 10.6023/cjoc202505007

Abstract

A transition-metal-free strategy for the synthesis of carboline derivatives via sequential dual C—N bond formation in a one-pot reaction is reported. Using 2,2'-dihalogenated pyridyl biaryls and primary amines as starting materials,this method efficiently constructs a series of α-, β-, γ- and δ-carbolines under alkaline conditions. The reaction proceeds smoothly in the presence of lithium tert-butoxide (t-BuOLi) or cesium carbonate (Cs2CO3) without requiring transition metal catalysts, demonstrating good functional group tolerance. This approach enables gram-scale synthesis and has been successfully applied to the preparation of the organic material 2,6-CbPy, achieving high conversion efficiency.

1 Introduction

Carbolines represent a class of fused tricyclic nitrogen-containing heterocycles characterized by their indole and pyridine moieties, serving as core scaffolds of numerous natural products and drug molecules. These structurally diverse tricycles are systematically classified into α-, β-, γ- and δ- carbolines based on the position of the nitrogen atom in the fused pyridine ring.[1] As privileged motifs, these heterocyclic architectures are extensively present in biologically active natural products and medicinal compounds.[2] Carbolines exhibit a wide range of important medicinal activities. For instance, grossularine-1 and grossularine-2, isolated from the tunicate Dendrodoa grossularia, exhibit cytotoxic activity against L1210 leukemia cells.[3] Mescengricin, the first natural product featuring an α-carboline chromophore, was obtained from Streptomyces griseoflavus as a reddish-brown powder.[4] Harmine and harmane are tricyclic β-carboline alkaloids originally isolated from seeds of Peganum harmala.[5] Harmine exhibits diverse pharmacological properties, including antimicrobial,[6] antitumor,[7] antiplasmodial[8] and hallucinogenic[9] properties. Harmane demonstrates vasorelaxant effects, which may underlie its hypotensive activity.[10] Additionally, abecarnil, a β-carboline alkaloid, exhibits notable anxiolytic[11] and anticonvulsant[12] activities. The structure diversity of carbolines extends further γ- and δ-carboline derivatives, exemplified by ingenine B (a γ-carboline alkaloid)[13] and cryptolepine (a δ-carboline alkaloid),[14] both of which display significant bioactivity (Figure 1).
Figure 1 Bioactive compounds with carboline derivatives
In view of the importance of the carboline scaffolds, especially in medicinal chemistry, the development of green and practical synthetic methodologies for these compounds has become increasingly crucial. Traditional methods such as the Pictet-Spengler reaction,[15] and the Bischler-Napie- ralski[16] cyclization are the most widely explored methods for the synthesis of β- and γ-carboline derivatives. Nevertheless, the development of novel synthetic strategies to access structurally diverse carboline derivatives remains in high demand. In recent years, several new protocols have been developed for the synthesis of β- and γ-carboline derivatives by using a variety of starting materials and metal catalysts. Various catalytic systems, including palladium, copper, ruthenium, rhodium and gold catalysts, have been successfully employed in the synthesis of these carboline derivatives.[17] Notably, Langer and coworkers developed an efficient method involving copper- and palladium-catal- yzed C—N coupling reactions of 2,2'-dibromobiaryl compounds with aromatic amines to synthesize carboline derivatives, which were prepared by regioselective Suzuki reactions of 3,4-dibromopyridine with o-bromophenyl- boronic acid followed by sequential Buchwald-Hartwig amination.[18] Chowdhury’s group reported a facile method for the divergent synthesis of α-carbolines via palladium- catalyzed [3+3] annulations of tosyliminoindolines with α,β-unsaturated aldehydes.[19] Subsequently, Wen and coworkers[20] developed a series of novel heterocyclic iodoniums, which were employed to construct various complex polycyclic heteroarenes through tandem dual arylations. In 2022, Roesner’s group[21] reported a synthetic route to α- and β-carbolines from fluoropyridines and 2- haloanilines. In our pursuit of more sustainable chemistry, we have primarily focused on transition metal-free C—N bond construction, particularly through a base-mediated coupling reaction. Herein, we report a base-mediated coupling protocol for the synthesis of carboline derivatives from 2,2'-dihalobiaryl compounds and primary amines. Noteworthy features of our protocol include mild reaction conditions, simple experimental procedures, broad substrate scope and general applicability, enabling the universal synthesis of carboline derivatives, encompassing α-, β-, γ-, and δ-substituted derivatives (Figure 2).
Figure 2 Strategies for carboline synthesis

2 Results and discussion

4-(2-Bromophenyl)-3-fluoropyridine is recognized as a versatile building block for the synthesis of various heterocyclic compounds. In this study, we report the reactivity of substituted 4-(2-bromophenyl)-3-fluoropyridine with tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate in the presence of lithium tert-butoxide (t-BuOLi) as a base, leading to the formation of functionalized carboline derivatives. A notable advantage of this reaction is the sequential formation of dual C—N bonds in a one-pot synthesis.
Our study began by reacting 1a with 2a in the presence of t-BuOK in dimethyl sulfoxide (DMSO) at 120 ℃ under an argon atmosphere for 12 h (Table 1). From this reaction, a carboline derivative 3aa was obtained in a 30% yield under this condition (Table 1, Entry 1). Encouraged by this preliminary result, we undertook further optimization of the reaction conditions. Various inorganic and orga- nic bases were first evaluated, finding that t-BuOLi pro-vided the best result, increasing the yield of 3aa to 33% (Table 1, Entry 2). Other bases such as Cs2CO3, NaOH, NaH and DIPEA were not effective for the reaction (Table 1, Entries 3~8). Next, the effect of other solvents, such as NMP, toluene, acetonitrile and N,N-dimethylformamide (DMF), was explored, which was not beneficial for the current transformation. The results indicated that DMSO was the most effective solvent, yielding a higher amount of 3aa compared to all other tested solvents (Table 1, Entries 9~12). These results demonstrate the critical role of both the base and the solvent in the efficiency of the reaction. Subsequently, increasing the equivalent of base to 6.0 equiv. resulted in a significant enhancement of the yield to 60% (Table 1, Entry 13). Further optimization by extending the reaction time to 24 h and decreasing the temperature to 100 ℃ led to an improved yield of 73% (Table 1, Entries 14~15). Finally, reducing the solvent volume to 0.5 mL afforded an isolated yield of 80% for compound 3aa (Entry 16). Reducing the equivalent of t-BuOLi or lowering the reaction temperature both resulted in dec-reased yields (Entries 17~18). Notably, no reaction occurred in the absence of t-BuOK (Entry 19).
Table 1 Optimization of reaction conditionsa
Entry Base Solvent T/℃ Yieldb/%
1 t-BuOK DMSO 120 30
2 t-BuOLi DMSO 120 33
3 t-BuONa DMSO 120 25
4 LiHMDS DMSO 120 9
5 Cs2CO3 DMSO 120 9
6 NaOH DMSO 120 17
7 NaH DMSO 120 25
8 DIPEA DMSO 120 ND
9 t-BuOLi DMF 120 9
10 t-BuOLi NMP 120 NR
11 t-BuOLi PhCH3 120 ND
12 t-BuOLi MeCN 120 ND
13c t-BuOLi DMSO 120 60
14c,d t-BuOLi DMSO 120 66
15c,d t-BuOLi DMSO 100 73
16c,d,e t-BuOLi DMSO 100 82 (80)f
17d,e,g t-BuOLi DMSO 100 70
18c,d,e t-BuOLi DMSO 80 43
19d,e DMSO 100 NR

a Reaction conditions: 1a (0.1 mmol, 1.0 equiv.), 2a (0.12 mmol, 1.2 equiv.), base (2.0 equiv.), solvent (1.0 mL), 120 ℃, 12 h. b Yield determined by 1H NMR analysis with 1,3,5-trimethoxybenzene as an internal standard. NR=no reaction, ND=not detected. c t-BuOLi (6.0 equiv.). d t=24 h. e DMSO (0.5 mL). f Isolated yield. g t-BuOLi (5.0 equiv.).

When the optimized reaction conditions were established, the substrate scope of this transformation using different 2,2'-dihalogenated pyridyl biaryls (Table 2). A series of products were successfully synthesized. When substrate 1 contains electron-donating or electron-withdrawing groups, the β-carboline products can be obtained in moderate to good yields (3ba~3ja). The structure of 3ca was configurationally confirmed via single crystal X-ray analysis. Furthermore, an α-carboline derivative was isolated in 83% yield (3ka). However, the yield of the obtained α-car- boline derivatives decreased when the pyridine derivatives contained an electron-withdrawing trifluoromethyl group (3la). Additionally, when a methyl group was present, increasing the temperature to 120 ℃ resulted in a 50% yield of the α-carboline derivative (3ma). Similarly, this method could be employed to obtain γ- and δ-carboline derivatives (3na~3oa). The reaction proceeded smoothly with moderate to high yields when using bipyridine derivatives, regardless of the position of the nitrogen atoms on the bipyridine framework (3pa~3sa). To demonstrate the preparative utility of the strategy, gram-scale reactions were carried out, affording the desired products 3ca and 3ia without a significant decrease in efficiency.
Table 2 Substrate scope with 2,2'-dihalogenated pyridyl biarylsa,b

a Reaction conditions: 1 (0.1 mmol, 1.0 equiv.), 2a (0.12 mmol, 1.2 equiv.), t-BuOLi (0.6 mmol, 6.0 equiv.), DMSO (0.5 mL), 100 ℃, 24 h, b Isolated yield. c 2a (0.2 mmol, 2.0 equiv.). d 120 ℃.

Next, the scope of N-heterocycles was investigated. Pyridine, quinoline and isoquinoline were all found to be viable amine substrates (Table 3). These heteroaryl amines reacted well to obtain 3ab~3ag in 55%~89% yields un-der the standard conditions. Subsequently, the scope of aromatic amines was evaluated. With regard to potentially reactive functional groups, some variety of functionalities, such as methoxy (3ai~3al), N,N-dimethyl (3am), thiomethyl (3an), tert-butyl (3ao), halogens (3aq~3as) and ethyl (3ap) at the para- or meta-positions of the phenyl rings were tolerated to provide 3ah~3as in 40%~78% yields. Notably, the sterically crowded amines, such as 1-naphth- ylamine (3at), benzo[d][1,3] dioxol-5-amine (3au) and quinoline amines (3av, 3aw) were also well tolerated.
Table 3 Substrate scope with aromatic aminesa,b

a Reaction conditions: 1a (0.1 mmol, 1.0 equiv.), 2 (0.12 mmol, 1.2 equiv.), t-BuOLi (0.6 mmol, 6.0 equiv.), DMSO (0.5 mL), 100 ℃, 24 h, b Isolated yield. c 2 (0.2 mmol, 2.0 equiv.).

Then, the scope of aliphatic amine nucleophiles was evaluated using 4-phenylpyridine N-oxides under basic conditions. The benzylamine, 2-phenylethan-1-amine and 3-phenylpropylamine reacted smoothly with 4a to give the desired products 6ab, 6ac and 6ad in 72%, 83% and 72% yields, respectively. Notably, primary aliphatic amines 5e~5g furnished the corresponding β-carboline products 6ae~6ag in 45%~55% yields. Satisfactorily, the electron-rich 4-phenylpyridine N-oxides substituted at the meta- (4b), and para- (4c) positions of the phenyl ring worked well with 5d to afford the desired products 6bd and 6cd in moderate yields. Importantly, the synthetically valuable cyano functional group remained intact, as evidenced by the formation of product (6dd) (Table 4).
Table 4 Substrate scope with 4-phenylpyridine N-oxides and alkylaminesa,b

a Reaction conditions: 4 (0.1 mmol, 1.0 equiv.), 5 (0.5 mmol, 5.0 equiv.), Cs2CO3 (0.4 mmol, 4.0 equiv.), DMSO (0.2 mL), 120 ℃, 15 h. b Isolated yield.

To demonstrate the synthetic utility of the obtained β-carbolines, several synthetic applications were performed (Scheme 1). The Suzuki-Miyaura cross-coupling of 3ia with phenylboronic acid produced 4-phenyl-β-car- bolines 3ia-1 in high yield. The alkyne functionality was introduced by the Sonogashira reaction under palladium- catalyzed condition giving the desired alkynes 3ia-2 in acceptable yield. N-Phenyl-6-amino-β-carboline 3ia-3 was obtained in moderate yield through Buchwald-Hartwig cross-coupling of 3ia with aniline. Meanwhile, this strate- gy can also be applied to the synthesis of material molecules. 2,6-CbPy, an organic optoelectronic material with strong electron transport capability and excellent hole transport properties, was synthesized from 3-(2-bromo-phenyl)-2-fluoropyridine and 2,6-diamino pyridine under standard conditions in 56% yield (Scheme 2).
Scheme 1 Synthesis of a series of 6-substituted β-carbolines
Scheme 2 Synthesis of 2,6-CbPy
To gain deeper insight into the transition-metal-free me- chanism, we isolated intermediate 6ad-2 and conducted an experiment under standard conditions, successfully achie- ving cyclization to yield the target product 6ad (Scheme 3).
Scheme 3 Mechanistic experiment
Based on the experimental results and previous reports, we have proposed a possible mechanistic pathway. The t-BuOLi base initially deprotonates the aryl amine 2 to form an anionic intermediate A, then attacks the fluoro- arene 1, via an intermolecular nucleophilic aromatic substitution (SNAr) to afford the arylated product B. Subsequently, the intermediate B undergoes further deprotonation to form an anionic intermediate C, which engages in an intramolecular SNAr reaction through displacing a halide anion and restoring aromaticity to deliver the target compound 3 (Scheme 4).
Scheme 4 Proposed reaction mechanism

3 Conclusions

In summary, we have established a novel base-promo- ted, transition-metal-free annulation strategy for the efficient construction of carboline derivatives. This method is characterized by mild reaction conditions, straightforward experimental operations, and broad substrate compatibility, enabling the versatile synthesis of α-, β-, γ- and δ- carboline architectures. Moreover, this method can also be applied to the synthesis of material molecules such as 2,6-CbPy. The developed protocol provides a practical, cost-effective and environmentally friendly approach for the synthesis of diversified carboline derivatives.

4 Experimental section

4.1 General experimental information

DMSO (anhydrous, 99.7%), tetrahydrofuran (THF) (anhydrous, 99.5%), and DMF (anhydrous, 99.8%) were purchased from Adamas and used without further purification. Reagents were purchased at the highest commercial quality and used without further purification, unless otherwise stated. Lithium tert-butoxide (t-BuOLi) was purchased from J&K Scientific, and cesium carbonate (Cs2CO3) was purchased from Bide. 4 Å molecular sieves were purchased from Adamas and activated under flame dry for 30 min prior to use. Yields refer to chromatographically and spectroscopically (1H NMR) homogeneous material, unless otherwise stated. Reactions were monitored by mass spectrometer (MS), liquid chromatograph mass spectrometer (LC-MS), and thin-layer chromatography (TLC). TLC was performed using 0.25 mm Leyan silica plates (60GF-254), and using short-wave UV light as the visualizing agent. 1H NMR, 13C NMR, and 19F NMR spectra were recorded on a Bruker DRX-500 instrument and calibrated using residual undeuterated solvent (CDCl3 at δ 7.26 for 1H NMR, δ 77.16 for 13C NMR; DMSO-d6 at δ 2.50 for 1H NMR, δ 39.52 for 13C NMR). High-resolution mass spectra (HRMS) were recorded on an Exactive Plus mass spectrometer. Column chromatography was performed using Adamas silica (60, particle size 0.040~0.063 mm), and preparative thin-layer chromatography (pTLC) was performed on Sinopep silica plates (HF254).

4.2 Experimental procedures

4.2.1 Typical procedure for the synthesis of 3

A 10 mL oven-dried Schlenk tube equipped with a magnetic stirrer was charged with compound 1 (0.1 mmol, 1.0 equiv.), arylamine 2 (0.12 mmol, 1.2 equiv.), and t-BuOLi (0.6 mmol, 6.0 equiv.). Then, the tube was evacuated and backfilled with nitrogen three times. Subsequently, 0.5 mL of dry DMSO was added using a syringe under nitrogen. The tube was then sealed, and the mixture was stirred at 100 ℃ for 24 h. After that, the resulting mixture was quenched with H2O and extracted with EtOAc (10 mL×3). The combined organic phase was washed with brine (10 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give a residue. The residue was purified by pTLC to afford the desired product 3.
tert-Butyl 4-(6-(3-chloro-9H-pyrido[3,4-b]indol-9-yl)- pyridin-3-yl)piperazine-1-carboxylate (3aa): White solid, 37.0 mg, 80% yield. m.p. 72~74 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.87 (s, 1H), 8.36 (d, J=2.5 Hz, 1H), 8.12 (d, J=7.8 Hz, 1H), 7.98 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.58 (t, J=7.8 Hz, 1H), 7.50~7.44 (m, 2H), 7.35 (t, J=7.5 Hz, 1H), 3.67~3.65 (m, 4H), 3.30~3.28 (m, 4H), 1.51 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.74, 145.89, 142.46, 141.60, 141.49, 137.92, 135.54, 133.34, 132.88, 129.64, 125.57, 122.05, 121.49, 121.25, 119.23, 114.48, 111.73, 80.40, 48.69, 43.02, 28.56; 19F NMR (471 MHz, CDCl3) δ: —131.31 (s). HRMS (ESI) calcd for C25H27- ClN5O2 [M+H] 464.1848, found 464.1842.
tert-Butyl 4-(6-(9H-pyrido[3,4-b]indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ba): Yellow solid, 12.0 mg, 28% yield. m.p. 50~52 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.16 (s, 1H), 8.54 (d, J=5.2 Hz, 1H), 8.40 (d, J=2.9 Hz, 1H), 8.17 (d, J=7.8 Hz, 1H), 8.00 (d, J=5.0 Hz, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.61~7.58 (m, 1H), 7.53 (d, J=8.7 Hz, 1H), 7.47 (dd, J=8.8, 3.0 Hz, 1H), 7.35 (t, J=7.3 Hz, 1H), 3.69 (t, J=5.0 Hz, 4H), 3.32 (t, J=5.0 Hz, 4H), 1.53 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.76, 145.80, 142.88, 140.77, 140.23, 137.97, 136.27, 134.13, 129.72, 128.89, 125.67, 122.13, 121.85, 121.22, 119.44, 114.60, 111.63, 80.39, 48.80, 43.11, 28.57. HRMS (ESI) calcd for C25H28N5O2 [M+H] 430.2238, found 430.2245.
tert-Butyl 4-(6-(3-chloro-6-methoxy-9H-pyrido[3,4-b]- indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ca): Yellow solid, 38.4 mg, 78% yield. m.p. 80~83 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.89 (s, 1H), 8.35 (d, J=2.0 Hz, 1H), 7.94 (s, 1H), 7.69 (d, J=9.1 Hz, 1H), 7.53 (d, J=2.5 Hz, 1H), 7.46 (d, J=4.1 Hz, 2H), 7.22 (dd, J=9.1, 2.5 Hz, 1H), 3.94 (s, 3H), 3.67 (t, J=5.0 Hz, 4H), 3.29 (t, J=5.0 Hz, 4H), 1.52 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.99, 154.63, 145.56, 142.62, 140.87, 137.73, 136.31, 135.62, 133.38, 132.47, 125.57, 121.55, 119.33, 118.67, 114.22, 112.74, 103.44, 80.27, 55.96, 48.63, 43.46, 28.44. HRMS (ESI) calcd for C26H29ClN5O3 [M+H] 494.1954, found 494.1960.
tert-Butyl 4-(6-(3-chloro-7-methoxy-9H-pyrido[3,4-b]- indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3da): Yellow solid, 36.0 mg, 73% yield. m.p. 78~80 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.69 (s, 1H), 8.31 (s, 1H), 7.91 (d, J=8.5 Hz, 1H), 7.80 (s, 1H), 7.41 (s, 2H), 7.12 (s, 1H), 6.90 (d, J=8.5 Hz, 1H), 3.84 (s, 3H), 3.63 (s, 4H), 3.26 (s, 4H), 1.49 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 161.72, 154.62, 145.73, 143.20, 142.19, 141.47, 137.70, 135.66, 132.98, 132.27, 125.40, 122.74, 119.10, 114.65, 113.46, 110.77, 95.03, 80.27, 55.68, 48.46, 43.08, 28.44. HRMS (ESI) calcd for C26H29ClN5O3 [M+H] 494.1954, found 494.1960.
tert-Butyl 4-(6-(3-chloro-8-methoxy-9H-pyrido[3,4-b]- indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ea): White solid. 28.6 mg, 58% yield. m.p. 180~182 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.58 (s, 1H), 8.27 (d, J=2.8 Hz, 1H), 7.94 (s, 1H), 7.72 (d, J=7.9 Hz, 1H), 7.37 (dd, J=8.7, 3.0 Hz, 1H), 7.28~7.25 (m, 2H), 7.05 (d, J=7.9 Hz, 1H), 3.74 (s, 3H), 3.68 (t, J=5.1 Hz, 4H), 3.32 (t, J=5.1 Hz, 4H), 1.52 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.63, 147.39, 146.07, 143.26, 141.14, 137.06, 136.18, 133.46, 132.56, 131.49, 124.11, 122.98, 122.23, 121.73, 114.30, 114.17, 110.83, 80.25, 55.86, 48.48, 43.16, 28.44. HRMS (ESI) calcd for C26H29ClN5O3 [M+H] 494.1954, found 494.1958.
tert-Butyl 4-(6-(6-methoxy-9H-pyrido[3,4-b]indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3fa): Yellow solid, 30.7 mg, 67% yield. m.p. 56~57 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.45 (d, J=5.2 Hz, 1H), 8.33 (d, J=2.9 Hz, 1H), 7.92~7.91 (m, 1H), 7.69 (d, J=9.0 Hz, 1H), 7.56 (d, J=2.5 Hz, 1H), 7.47 (d, J=8.7 Hz, 1H), 7.41 (dd, J=8.8, 3.0 Hz, 1H), 7.18 (dd, J=9.0, 2.5 Hz, 1H), 3.92 (s, 3H), 3.64 (t, J=5.0 Hz, 4H), 3.25 (t, J=5.0 Hz, 4H), 1.49 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.86, 154.63, 145.45, 142.97, 139.62, 137.74, 136.38, 135.45, 134.17, 129.32, 125.65, 122.45, 118.87, 118.42, 114.37, 112.59, 103.49, 80.24, 55.98, 48.69, 43.29, 28.43. HRMS (ESI) calcd for C26H30N5O3 [M+H] 460.2344, found 460.2349.
tert-Butyl 4-(6-(3-chloro-8-(trifluoromethyl)-9H-pyrido- [3,4-b]indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ga): Yellow solid, 36.6 mg, 69% yield. m.p. 160~162 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.27~8.30 (m, 2H), 8.19 (s, 1H), 7.96 (s, 1H), 7.86 (d, J=7.6 Hz, 1H), 7.34~7.40 (m, 3H), 3.65 (t, J=5.1 Hz, 4H), 3.33 (t, J=5.1 Hz, 4H), 1.49 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.65, 147.20, 142.08, 141.65, 138.62, 137.48, 133.29, 131.39, 128.18 (d, J=5.7 Hz), 126.02, 123.99, 123.79, 123.40 (d, J=272.0 Hz), 123.22, 120.38, 115.04 (q, J=33.5 Hz), 114.13, 80.34, 47.97, 43.23, 28.49; 19F NMR (471 MHz, CDCl3) δ: —57.10. HRMS (ESI) calcd for C26H26ClF3N5O2 [M+H] 532.1722, found 532.1730.
tert-Butyl 4-(6-(3-chloro-6-(trifluoromethyl)-9H-pyrido- [3,4-b]indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ha): Yellow solid, 36.1 mg, 68% yield. m.p. 111~112 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.86 (s, 1H), 8.37 (d, J=15.2 Hz, 2H), 8.01 (s, 1H), 7.79 (s, 2H), 7.47 (s, 2H), 3.67 (t, J=5.1 Hz, 4H), 3.32 (t, J=5.1 Hz, 4H), 1.51 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.72, 146.28, 142.94, 142.18, 141.42, 137.87, 136.05, 133.73, 132.23, 126.24 (q, J=3.3 Hz), 125.33, 124.82 (q, J=234.5 Hz), 123.61 (q, J=4.6 Hz), 120.80, 119.75 (q, J=4.0 Hz), 119.36, 114.74, 112.25, 80.46, 48.43, 43.59, 28.53. 19F NMR (471 MHz, CDCl3) δ: —60.78. HRMS (ESI) calcd for C26H26ClF3N5O2 [M+H] 532.1722, found 532.1732.
tert-Butyl 4-(6-(6-bromo-3-chloro-9H-pyrido[3,4-b]in- dol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ia): Bro- wn solid, 27.0 mg, 50% yield. m.p. 118~100 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.83 (s, 1H), 8.33 (s, 1H), 8.20 (d, J=1.5 Hz, 1H), 7.90 (s, 1H), 7.64~7.59 (m, 2H), 7.43 (s, 2H), 3.65 (t, J=5.0 Hz, 4H), 3.29 (t, J=5.0 Hz, 4H), 1.50 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.62, 145.95, 141.71, 141.59, 140.08, 137.74, 135.50, 133.45, 132.30, 131.50, 125.35, 124.58, 122.70, 119.04, 114.51, 114.07, 113.29, 80.34, 48.44, 43.01, 28.44. HRMS (ESI) calcd for C25H26BrClN5O2 [M+H] 542.0953, found 542.0963.
tert-Butyl 4-(6-(3-chloro-7-fluoro-9H-pyrido[3,4-b]in- dol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ja): Yellow solid. Yellow solid, 13.0 mg, 27% yield. m.p. 85~88 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.80 (s, 1H), 8.35 (s, 1H), 8.05 (dd, J=8.6, 5.3 Hz, 1H), 7.92 (s, 1H), 7.46 (d, J=1.5 Hz, 2H), 7.42 (dd, J=9.9, 2.1 Hz, 1H), 7.08 (td, J=8.8, 2.2 Hz, 1H), 3.66 (t, J=5.2 Hz, 4H), 3.30 (t, J=5.2 Hz, 4H), 1.51 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 164.00 (d, J=246.9 Hz), 154.62, 145.98, 142.42 (d, J=12.5 Hz), 141.81 (d, J=8.1 Hz), 137.77, 135.94, 132.86, 132.42, 125.38, 123.25 (d, J=10.7 Hz), 118.95, 117.48, 114.11, 110.11 (d, J=24.8 Hz), 98.79 (d, J=27.7 Hz), 80.32, 48.45, 43.26, 28.44; 19F NMR (471 MHz, CDCl3) δ: —108.79 (s). HRMS (ESI) calcd for C25H26ClFN5O2 [M+H] 482.1754, found 482.1761.
tert-Butyl 4-(6-(9H-pyrido[2,3-b]indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ka): White solid, 35.6 mg, 83% yield. m.p. 94~96 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.48 (d, J=4.4 Hz, 1H), 8.36~8.34 (m, 2H), 8.08 (d, J=7.7 Hz, 1H), 7.96 (d, J=8.3 Hz, 1H), 7.87 (d, J=8.7 Hz, 1H), 7.51~7.45 (m, 2H), 7.33 (t, J=7.5 Hz, 1H), 7.23 (dd, J=7.7, 4.8 Hz, 1H), 3.63 (t, J=5.1 Hz, 4H), 3.23 (t, J=5.1 Hz, 4H), 1.50 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.65, 151.32, 146.06, 145.52, 142.80, 139.36, 137.36, 128.30, 127.22, 125.68, 121.21, 121.07, 120.87, 120.65, 116.99, 116.46, 112.34, 80.16, 48.95, 43.65, 28.46. HRMS (ESI) calcd for C25H28N5O2 [M+H] 430.2238, found 430.2245.
tert-Butyl 4-(6-(7-(trifluoromethyl)-9H-pyrido[2,3-b]- indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3la): Yellow solid, 19.8 mg, 40% yield. m.p. 178~180 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.55 (dd, J=4.8, 1.4 Hz, 1H), 8.41 (dd, J=7.7, 1.4 Hz, 1H), 8.36 (d, J=3.0 Hz, 1H), 8.29 (s, 1H), 8.16 (d, J=8.1 Hz, 1H), 7.91 (d, J=8.8 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.49 (dd, J=8.8, 3.1 Hz, 1H), 7.29 (dd, J=7.7, 4.8 Hz, 1H), 3.65 (t, J=5.0 Hz, 4H), 3.28 (t, J=5.0 Hz, 4H), 1.50 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.77, 152.05, 147.61, 145.90, 142.20, 138.67, 137.45, 129.28, 129.00 (q, J=32.1 Hz), 125.66, 124.76 (q, J=272.6 Hz), 123.78, 121.11, 120.92, 117.95 (q, J=3.9 Hz), 117.13, 116.04, 110.21 (q, J=4.4 Hz), 80.33, 48.90, 43.39, 28.55; 19F NMR (471 MHz, CDCl3) δ: —61.15. HRMS (ESI) calcd for [M+H] C26H27F3N5O2 498.2112, found 498.2118.
tert-Butyl 4-(6-(7-methyl-9H-pyrido[2,3-b]indol-9-yl)- pyridin-3-yl)piperazine-1-carboxylate (3ma): White solid, 22.1 mg, 50% yield. m.p. 159~162 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.43 (dd, J=4.9, 1.5 Hz, 1H), 8.36 (d, J=3.0 Hz, 1H), 8.29 (dd, J=7.6, 1.5 Hz, 1H), 7.95 (d, J=7.9 Hz, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.74 (s, 1H), 7.47 (dd, J=8.8, 3.1 Hz, 1H), 7.20 (dd, J=7.6, 4.9 Hz, 1H), 7.15 (d, J=7.9 Hz, 1H), 3.64 (t, J=5.0 Hz, 4H), 3.25 (t,J=5.0 Hz, 4H), 2.52 (s, 3H), 1.50 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.66, 151.49, 145.48, 142.87, 139.76, 137.59, 137.41, 127.78, 125.72, 122.67, 120.99, 120.36, 118.73, 117.10, 116.37, 112.27, 80.16, 48.98, 43.18, 28.45, 22.37. HRMS (ESI) calcd for C26H30N5O2 [M+H] 444.2395, found 444.2399.
tert-Butyl 4-(6-(5H-pyrido[4,3-b]indol-5-yl)pyridin-3-yl)piperazine-1-carboxylate (3na): Brown solid, 27.0 mg, 63% yield. m.p. 71~73 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.35 (s, 1H), 8.52 (d, J=5.7 Hz, 1H), 8.35 (d, J=2.7 Hz, 1H), 8.17 (d, J=7.7 Hz, 1H), 7.68 (d, J=8.3 Hz, 1H), 7.55 (d, J=5.8 Hz, 1H), 7.50 - 7.42 (m, 3H), 7.37 (t, J=7.5 Hz, 1H), 3.65 (t, J=5.0 Hz, 4H), 3.28 (t, J=5.0 Hz, 4H), 1.50 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.62, 145.89, 145.25, 144.24, 142.66, 142.23, 140.00, 137.79, 127.16, 125.32, 122.08, 121.78, 120.46, 119.60, 111.11, 106.09, 80.30, 48.53, 43.33, 28.44. HRMS (ESI) calcd for C25H28N5O2 [M+H] 430.2238, found 430.2244.
tert-Butyl 4-(6-(5H-pyrido[3,2-b]indol-5-yl)pyridin-3-yl)piperazine-1-carboxylate (3oa): Yellow solid, 19.7 mg, 46% yield. m.p. 151~154 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.60 (dd, J=4.7, 1.2 Hz, 1H), 8.42 (d, J=7.8 Hz, 1H), 8.34 (d, J=2.8 Hz, 1H), 8.02 (dd, J=8.3, 1.2 Hz, 1H), 7.72 (d, J=8.3 Hz, 1H), 7.54~7.51 (m, 1H), 7.47 (d, J=8.7 Hz, 1H), 7.43 (dd, J=8.8, 3.0 Hz, 1H), 7.39~7.36 (m, 1H), 7.33 (dd, J=8.3, 4.7 Hz, 1H), 3.65 (t, J=5.1 Hz, 4H), 3.26 (t, J=5.1 Hz, 4H), 1.50 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.64, 145.51, 142.97, 142.92, 142.57, 140.51, 137.78, 133.55, 128.07, 125.59, 122.96, 121.29, 120.89, 120.35, 119.23, 118.25, 110.84, 80.27, 48.71, 43.31, 28.45. HRMS (ESI) calcd for C25H28N5O2 [M+H] 430.2238, found 430.2242.
tert-Butyl 4-(6-(9H-pyrrolo[2,3-b:5,4-b']dipyridin-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3pa): Yellow solid, 23.6 mg, 55% yield. m.p. 151~154 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.53 (d, J=4.8 Hz, 2H), 8.42 (d, J=2.8 Hz, 1H), 8.33 (d, J=7.6 Hz, 2H), 7.63 (d, J=8.7 Hz, 1H), 7.45 (dd, J=8.7, 2.9 Hz, 1H), 7.27~7.24 (m, 2H), 3.61 (t, J=5.1 Hz, 4H), 3.25 (t, J=5.1 Hz, 4H), 1.48 (s, 9H); 13C NMR (126 MHz, CD3OD) δ: 156.32, 152.53, 148.63, 148.07, 140.67, 138.25, 131.37, 126.58, 124.95, 118.72, 115.95, 81.49, 49.29, 44.32, 28.67. HRMS (ESI) calcd for C24H27N6O2 [M+H] 431.2190, found 431.2190.
tert-Butyl 4-(6-(9H-pyrrolo[2,3-c:5,4-c']dipyridin-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3qa): Yellow solid, 37.4 mg, 87% yield. m.p. 78~83 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.26 (s, 2H), 8.57 (d, J=4.8 Hz, 2H), 8.35 (d, J=2.9 Hz, 1H), 8.03 (d, J=5.0 Hz, 2H), 7.53 (d, J=8.7 Hz, 1H), 7.46 (dd, J=8.7, 2.9 Hz, 1H), 3.64 (t, J=5.0 Hz, 4H), 3.29 (t, J=5.0 Hz, 4H), 1.48 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.60, 145.98, 141.59, 140.35, 137.72, 136.24, 135.34, 127.72, 125.40, 118.83, 115.60, 80.28, 48.42, 43.11, 28.42. HRMS (ESI) calcd for C24H27N6O2 [M+H] 431.2190, found 431.2195.
tert-Butyl 4-(6-(9H-pyrrolo[2,3-b:5,4-c']dipyridin-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ra): Yellow solid, 21.5 mg, 50% yield. m.p. 78~80 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.72 (d, J=3.8 Hz, 2H), 8.32 (t, J=1.6 Hz, 1H), 8.08 (dd, J=8.4, 1.0 Hz, 2H), 7.45 (d, J=1.6 Hz, 2H), 7.40 (dd, J=8.4, 4.6 Hz, 2H), 3.65 (t, J=5.0 Hz, 4H), 3.27 (t, J=5.0 Hz, 4H), 1.49 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.61, 145.70, 144.34, 142.18, 140.89, 137.73, 134.23, 125.60, 121.79, 118.77, 118.70, 80.30, 48.60, 43.16, 28.43. HRMS (ESI) calcd for [M+H] C24H27N6O2 431.2190, found 431.2197.
tert-Butyl 4-(6-(5H-pyrrolo[3,2-b:4,5-b']dipyridin-5-yl)pyridin-3-yl)piperazine-1-carboxylate (3sa): Colourless liquid, 34.4 mg, 80% yield. 1H NMR (500 MHz, CDCl3) δ: 9.55 (s, 1H), 8.65 (dd, J=4.8, 1.6 Hz, 1H), 8.60~8.59 (m, 1H), 8.45 (dd, J=7.7, 1.6 Hz, 1H), 8.35 (d, J=3.0 Hz, 1H), 8.06 (d, J=8.9 Hz, 1H), 7.97 (d, J=5.1 Hz, 1H), 7.50 (dd, J=8.9, 3.1 Hz, 1H), 7.32 (dd, J=7.7, 4.8 Hz, 1H), 3.66 (t, J=5.0 Hz, 4H), 3.27 (t, J=5.0 Hz, 4H), 1.51 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.63, 151.32, 149.04, 145.59, 142.25, 140.88, 137.06, 136.18, 135.16, 130.25, 126.92, 125.54, 119.95, 117.10, 115.13, 114.65, 80.17, 48.83, 43.20, 28.43. HRMS (ESI) calcd for C24H27- N6O2 [M+H] 431.2190, found 431.2197.
3-Chloro-9-(pyridin-2-yl)-9H-pyrido[3,4-b]indole (3ab): White solid, 17.3 mg, 62% yield. m.p. 154~156 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.04 (s, 1H), 8.73 (dd, J=4.8, 1.1 Hz, 1H), 8.12 (d, J=7.8 Hz, 1H), 7.99~7.96 (m, 2 H), 7.88 (d, J=8.4 Hz, 1H), 7.64 (d, J=8.1 Hz, 1H), 7.60 (ddd, J=8.4, 7.1, 1.1 Hz, 1H), 7.39~7.35 (m, 2H); 13C NMR (126 MHz, CDCl3) δ: 150.84, 149.96, 141.99, 141.05, 139.00, 135.16, 133.84, 133.39, 129.79, 122.05, 122.03, 121.97, 121.69, 118.48, 114.47, 112.08. HRMS (ESI) calcd for C16H11ClN3 [M+H] 280.0637, found 280.0631.
3-Chloro-9-(pyridin-3-yl)-9H-pyrido[3,4-b]indole (3ac): White solid, 22.3 mg, 80% yield. m.p. 170~172 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.90 (s, 1H), 8.79 (d, J=4.4 Hz, 1H), 8.52 (s, 1H), 8.15 (d, J=7.9 Hz, 1H), 8.01 (s, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.63~7.58 (m, 2H), 7.42~7.37 (m, 2H); 13C NMR (126 MHz, CDCl3) δ: 149.47, 148.22, 142.48, 141.83, 136.23, 134.36, 133.58, 132.84, 131.59, 130.00, 124.92, 122.38, 121.75, 121.08, 114.85, 110.38. HRMS (ESI) calcd for C16H11ClN3 [M+H] 280.0637, found 280.0630.
3-Chloro-9-(pyridin-4-yl)-9H-pyrido[3,4-b]indole (3ad): White solid, 19.5 mg, 70% yield. m.p. 200~201 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.90 (d, J=4.5 Hz, 2H), 8.69 (s, 1H), 8.14 (d, J=7.9 Hz, 1H), 7.99 (s, 1H), 7.63~7.56 (m, 4H), 7.40 (ddd, J=7.9, 6.0, 2.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 152.18, 144.43, 142.33, 141.27, 135.14, 133.36, 131.93, 130.08, 122.44, 122.22, 121.54, 120.35, 114.89, 110.76. HRMS (ESI) calcd for C16H11ClN3 [M+H] 280.0637, found 280.0632.
3-Chloro-9-(5-methoxypyridin-2-yl)-9H-pyrido[3,4-b]indole (3ae): White solid, 21.6 mg, 70% yield. m.p. 159~161 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.86 (s, 1H), 8.39 (d, J=3.0 Hz, 1H), 8.11 (d, J=7.9 Hz, 1H), 7.97 (s, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.60~7.56 (m, 1H), 7.53 (d, J=8.7 Hz, 1H), 7.47 (dd, J=8.7, 3.0 Hz, 1H), 7.35 (t, J=7.5 Hz, 1H), 3.97 (s, 3H); 13C NMR (126 MHz, CDCl3) δ: 154.68, 143.45, 141.53, 136.80, 135.49, 133.26, 132.92, 129.68, 123.78, 122.04, 121.56, 121.25, 119.50, 114.47, 111.64, 56.20. HRMS (ESI) calcd for C17H13ClN3O [M+H] 310.0742, found 310.0737.
3-Chloro-9-(quinolin-4-yl)-9H-pyrido[3,4-b]indole (3af): White solid, 29.2 mg, 89% yield. m.p. 172~174 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.17 (d, J=4.4 Hz, 1H), 8.33 (d, J=8.5 Hz, 1H), 8.25 (s, 1H), 8.21 (d, J=7.9 Hz, 1H), 8.08 (s, 1H), 7.84 (ddd, J=8.3, 6.7, 1.3 Hz, 1H), 7.59 (d, J=4.5 Hz, 1H), 7.55~7.52 (m, 1H), 7.50~7.47 (m, 1H), 7.41 (dd, J=16.5, 8.4 Hz, 2H), 7.13 (d, J=8.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 151.09, 150.44, 143.04, 141.94, 141.60, 136.75, 132.93, 132.36, 130.89, 130.59, 129.95, 128.04, 125.09, 123.16, 122.36, 121.81, 121.19, 120.13, 114.91, 111.25. HRMS (ESI) calcd for C20H13ClN3 [M+H] 330.0793, found 330.0786.
3-Chloro-9-(isoquinolin-4-yl)-9H-pyrido[3,4-b]indole (3ag): Brown solid, 18.0 mg, 55% yield. m.p. 137~138 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.49 (s, 1H), 8.74 (s, 1H), 8.23~8.20 (m, 3H), 8.09 (s, 1H), 7.74 (t, J=7.3 Hz, 1H), 7.65~7.62 (m, 1H), 7.54~7.51 (m, 1H), 7.39 (t, J=7.4 Hz, 1H), 7.27~7.25 (m, 1H), 7.08 (d, J=8.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 153.99, 143.81, 143.27, 141.63, 137.43, 133.30, 132.61, 132.20, 132.08, 129.90, 129.70, 128.72, 128.57, 128.12, 122.32, 121.92, 121.49, 120.92, 114.88, 111.02. HRMS (ESI) calcd for C20H13ClN3 [M+H] 330.0793, found 330.0786.
3-Chloro-9-phenyl-9H-pyrido[4-b]indole (3ah): Bro- wn solid, 16.6 mg, 60% yield. m.p. 104~106 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.55 (s, 1H), 8.14 (d, J=7.9 Hz, 1H), 8.01 (s, 1H), 7.64 (t, J=7.8 Hz, 2H), 7.58~7.51 (m, 4H), 7.45 (d, J=8.4 Hz, 1H), 7.36 (d, J=7.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 142.70, 141.13, 136.54, 136.38, 132.35, 132.10, 130.37, 129.58, 128.42, 126.83, 122.15, 121.09, 120.76, 114.60, 110.84. HRMS (ESI) calcd for C17H12ClN2 [M+H] 279.0684, found 279.0679.
3-Chloro-9-(2-methoxyphenyl)-9H-pyrido[3,4-b]indole (3ai): Brown solid, 17.8 mg, 58% yield. m.p. 39~41 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.28 (d, J=1.0 Hz, 1H), 8.14 (d, J=7.8 Hz, 1H), 8.01 (d, J=0.9 Hz, 1H), 7.56~7.52 (m, 2H), 7.46 (dd, J=7.6, 1.6 Hz, 1H), 7.34~7.31 (m, 1H), 7.24~7.16 (m, 3H), 3.73 (s, 3H); 13C NMR (126 MHz, CDCl3) δ: 155.57, 143.07, 140.65, 136.50, 132.73, 132.18, 130.37, 129.40, 129.31, 124.52, 121.98, 121.45, 120.74, 114.51, 112.83, 111.17, 55.76. HRMS (ESI) calcd for C18H14ClN2O [M+H] 309.0790, found 309.0781.
3-Chloro-9-(3-methoxyphenyl)-9H-pyrido[3,4-b]indole (3aj): Brown solid, 20.3 mg, 66% yield. m.p. 136~137 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.59 (s, 1H), 8.14 (d, J=7.9 Hz, 1H), 8.00 (s, 1H), 7.59~7.48 (m, 3H), 7.35 (t, J=7.5 Hz, 1H), 7.14 (d, J=7.8 Hz, 1H), 7.08~7.05 (m, 2H), 3.87 (s, 3H); 13C NMR (126 MHz, CDCl3) δ: 161.13, 142.62, 141.14, 137.61, 136.30, 132.36, 132.25, 131.08, 129.59, 122.13, 121.10, 120.77, 118.88, 114.58, 114.07, 112.47, 110.99, 55.70. HRMS (ESI) calcd for C18H14ClN2O [M+H] 309.0790, found 309.0783.
3-Chloro-9-(4-methoxyphenyl)-9H-pyrido[3,4-b]indole (3ak): Brown solid, 15.4 mg, 50% yield. m.p. 103~105 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.50 (s, 1H), 8.16 (d, J=7.9 Hz, 1H), 8.03 (s, 1H), 7.58 (t, J=7.7 Hz, 1H), 7.46 (d, J=8.8 Hz, 2H), 7.41~7.34 (m, 2H), 7.16 (d, J=8.8 Hz, 2H), 3.95 (s, 3H); 13C NMR (126 MHz, CDCl3) δ: 159.56, 143.20, 140.90, 136.83, 132.08, 129.51, 129.00, 128.31, 122.11, 120.86, 120.54, 115.53, 114.55, 110.80, 55.78. HRMS (ESI) calcd for C18H14ClN2O [M+H] 309.0790, found 309.0782.
3-Chloro-9-(3,4-dimethoxyphenyl)-9H-pyrido[3,4-b]indole (3al): Yellow oil, 17.2 mg, 51% yield. 1H NMR (500 MHz, CDCl3) δ: 8.51 (s, 1H), 8.15 (dd, J=8.0, 1.0 Hz, 1H), 8.01 (d, J=1.0 Hz, 1H), 7.57 (ddd, J=8.4, 7.1, 1.2 Hz, 1H), 7.42~7.40 (m, 1H), 7.35 (ddd, J=8.0, 7.1, 0.9 Hz, 1H), 7.12~7.07 (m, 2H), 7.00 (d, J=2.1 Hz, 1H), 4.01 (s, 3H), 3.89 (s, 3H); 13C NMR (126 MHz, CDCl3) δ: 150.13, 149.09, 143.05, 140.85, 136.68, 132.04, 131.98, 129.46, 129.04, 122.04, 120.81, 120.44, 119.32, 114.47, 111.90, 110.74, 110.21, 56.22, 56.20. HRMS (ESI) calcd for C19H16ClN2O2 [M+H] 339.0895, found 339.0891.
4-(3-Chloro-9H-pyrido[3,4-b]indol-9-yl)-N,N-dimethyl-aniline (3am): Yellow solid, 19.2 mg, 60% yield. m.p. 42~44 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.49 (s, 1H), 8.13 (d, J=7.9 Hz, 1H), 8.00 (s, 1H), 7.54 (ddd, J=8.2, 6.9, 1.0 Hz, 1H), 7.39~7.30 (m, 4H), 6.89 (d, J=9.0 Hz, 2H), 3.08 (s, 6H); 13C NMR (126 MHz, CDCl3) δ: 150.25, 143.40, 140.45, 136.96, 132.17, 131.74, 129.20, 127.80, 124.61, 121.90, 120.43, 120.28, 114.33, 113.07, 110.87. HRMS (ESI) calcd for C19H17ClN3 [M+H] 322.1106, found 322.0736.
3-Chloro-9-(4-(methylthio)phenyl)-9H-pyrido[3,4-b]indole (3an): Brown solid, 16.2 mg, 50% yield. m.p. 123~126 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.52 (s, 1H), 8.14 (d, J=7.9 Hz, 1H), 8.00 (s, 1H), 7.57 (t, J=7.6 Hz, 1H), 7.47 (q, J=8.6 Hz, 4H), 7.42 (d, J=8.4 Hz, 1H), 7.35 (t, J=7.5 Hz, 1H), 2.59 (s, 3H); 13C NMR (126 MHz, CDCl3) δ: 142.76, 141.08, 139.43, 136.46, 133.22, 132.28, 131.98, 129.61, 127.82, 127.23, 122.15, 121.12, 120.73, 114.65, 110.80, 15.83. HRMS (ESI) calcd for C18H14ClN2S [M+H] 325.0561, found 325.0555.
9-(4-(tert-Butyl)phenyl)-3-chloro-9H-pyrido[3,4-b]indole (3ao): Yellow solid, 21.7 mg, 65% yield. m.p. 133~136 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.57 (s, 1H), 8.15 (d, J=7.9 Hz, 1H), 8.01 (s, 1H), 7.64 (d, J=8.6 Hz, 2H), 7.56 (ddd, J=8.3, 7.0, 1.3 Hz, 1H), 7.48~7.46 (dd, J=8.6, 2.4 Hz, 3H), 7.34 (ddd, J=8.0, 7.0, 1.1 Hz, 1H), 1.43 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 151.44, 142.75, 140.85, 136.37, 133.67, 132.15, 129.35, 127.14, 126.19, 121.98, 120.82, 120.58, 114.43, 110.90, 34.90, 31.40. HRMS (ESI) calcd for C21H20ClN2 [M+H] 335.1310, found 335.1324.
3-Chloro-9-(3-ethylphenyl)-9H-pyrido[3,4-b]indole (3ap): Brown solid, 12.2 mg, 40% yield. m.p. 114~115 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.57 (s, 1H), 8.15 (d, J=7.9 Hz, 1H), 8.01 (s, 1H), 7.59~7.53 (m, 2H), 7.47 (d, J=8.3 Hz, 1H), 7.38~7.33 (m, 4H), 2.78 (q, J=7.5 Hz, 2H), 1.32 (t, J=7.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ: 146.77, 142.63, 140.90, 136.41, 136.30, 132.19, 132.15, 130.09, 129.43, 127.91, 126.02, 123.86, 122.02, 120.89, 120.62, 114.46, 110.84, 28.78, 15.45. HRMS (ESI) calcd for C19H16ClN2 [M+H] 307.0997, found 307.1000.
3-Chloro-9-(4-fluorophenyl)-9H-pyrido[3,4-b]indole (3aq): Yellow solid, 19.2 mg, 65% yield. m.p. 183~185 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.48 (d, J=0.6 Hz, 1H), 8.15 (d, J=7.9 Hz, 1H), 8.01 (d, J=0.7 Hz, 1H), 7.58 (ddd, J=8.3, 7.1, 1.1 Hz, 1H), 7.54~7.51 (m, 2H), 7.39~7.32 (m, 4H); 13C NMR (126 MHz, CDCl3) δ: 162.21 (d, J=249.0 Hz), 142.89, 141.31, 136.57, 132.45(d, J=3.8 Hz), 132.36, 131.86, 129.73, 128.85 (d, J=8.7 Hz), 122.24, 121.24, 120.74, 117.47 (d, J=22.9 Hz), 114.69, 110.62. 19F NMR (471 MHz, CDCl3) δ: —112.07. HRMS (ESI) calcd for C17H11ClFN2 [M+H] 297.0590, found 297.0585.
3-Chloro-9-(4-chlorophenyl)-9H-pyrido[3,4-b]indole (3ar): Yellow solid, 14.3 mg, 46% yield. m.p. 178~180 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.52 (s, 1H), 8.14 (d, J=7.9 Hz, 1H), 8.00 (s, 1H), 7.60 (dd, J=22.0, 8.2 Hz, 3H), 7.50 (d, J=8.5 Hz, 2H), 7.41 (d, J=8.4 Hz, 1H), 7.37 (t, J=7.5 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 142.53, 141.45, 136.24, 135.06, 134.18, 131.85, 130.66, 129.76, 128.13, 122.26, 121.38, 120.87, 114.70, 110.62. HRMS (ESI) calcd for C17H11Cl2N2 [M+H] 313.0294, found 313.0289.
9-(4-Bromophenyl)-3-chloro-9H-pyrido[3,4-b]indole (3as): Brown solid, 22.7 mg, 64% yield. m.p. 180~183 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.55 (s, 1H), 8.16 (d, J=7.8 Hz, 1H), 8.02 (s, 1H), 7.80 (dd, J=6.7, 4.8 Hz, 2H), 7.62~7.59 (m, 1H), 7.47~7.43 (m, 3H), 7.39 (t, J=7.5 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 142.34, 141.38, 136.05, 135.50, 133.55, 132.45, 131.75, 129.68, 128.31, 122.17, 121.96, 121.31, 120.79, 114.61, 110.51. HRMS (ESI) calcd for C17H11BrClN2 [M+H] 356.9789, found 356.9785.
3-Chloro-9-(naphthalen-1-yl)-9H-pyrido[3,4-b]indole (3at): Brown solid, 25.5 mg, 78% yield. m.p. 156~158 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.22~8.19 (m, 2H), 8.11~8.09 (m, 2H), 8.04 (d, J=8.3 Hz, 1H), 7.71~7.67 (m, 1H), 7.64 (dd, J=7.2, 1.1 Hz, 1H), 7.59~7.55 (m, 1H), 7.49 (ddd, J=8.3, 7.0, 1.0 Hz, 1H), 7.36 (t, J=7.6 Hz, 2H), 7.21 (d, J=8.5 Hz, 1H), 7.06 (d, J=8.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 143.93, 141.07, 137.49, 134.95, 132.62, 132.45, 132.18, 130.49, 129.91, 129.58, 128.80, 127.55, 127.14, 126.60, 125.97, 122.80, 122.13, 120.98, 120.59, 114.68, 111.27. HRMS (ESI) calcd for C21H14ClN2 [M+H] 329.0841, found 329.0835.
9-(Benzo[d][1,3]dioxol-5-yl)-3-chloro-9H-pyrido[3,4-b]indole (3au): Brown solid, 24.1 mg, 75% yield. m.p. 112~114 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.51 (s, 1H), 8.13 (d, J=7.9 Hz, 1H), 8.00 (s, 1H), 7.57 (ddd, J=8.4, 7.2, 1.1 Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 7.36~7.33 (m, 1H), 7.03~7.97 (m, 3H), 6.13 (s, 2H); 13C NMR (126 MHz, CDCl3) δ: 148.97, 147.73, 143.00, 140.89, 136.63, 132.06, 131.98, 129.91, 129.50, 122.03, 120.90, 120.60, 120.45, 114.48, 110.74, 109.17, 107.99, 102.12. HRMS (ESI) calcd for C18H12ClN2O2 [M+H] 323.0582, found 323.0591.
3-Chloro-9-(quinolin-6-yl)-9H-pyrido[3,4-b]indole (3av): Brown solid, 18.7 mg, 57% yield. m.p. 107~109 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.06 (d, J=3.4 Hz, 1H), 8.62 (s, 1H), 8.40 (d, J=8.9 Hz, 1H), 8.27 (d, J=8.2 Hz, 1H), 8.18 (d, J=7.9 Hz, 1H), 8.04 (d, J=2.9 Hz, 2H), 7.91 (d, J=8.9 Hz, 1H), 7.61 (t, J=7.7 Hz, 1H), 7.56 (dd, J=8.2, 4.2 Hz, 1H), 7.52 (d, J=8.2 Hz, 1H), 7.40 (t, J=7.5 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 151.47, 147.38, 142.63, 141.53, 136.34, 136.15, 134.59, 132.63, 132.12, 131.92, 129.81, 129.03, 128.11, 125.01, 122.38, 122.30, 121.49, 120.95, 114.74, 110.70. HRMS (ESI) calcd for C20H13ClN3 [M+H] 330.0798, found 330.0787.
3-Chloro-9-(quinolin-5-yl)-9H-pyrido[3,4-b]indole (3aw): White solid, 23.6 mg, 72% yield. m.p. 226~227 ℃; 1H NMR (500 MHz, CDCl3) δ: 9.01 (dd, J=4.0, 1.2 Hz, 1H), 8.37 (d, J=8.6 Hz, 1H), 8.21 (d, J=7.9 Hz, 1H), 8.17 (s, 1H), 8.07 (s, 1H), 7.96~7.93 (m, 1H), 7.73 (d, J=7.3 Hz, 1H), 7.56 (d, J=8.5 Hz, 1H), 7.51 (t, J=7.7 Hz, 1H), 7.37 (t, J=7.5 Hz, 1H), 7.31 (dd, J=8.5, 4.1 Hz, 1H), 7.03 (d, J=8.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 151.59, 149.38, 143.83, 141.47, 137.44, 132.58, 132.35, 132.15, 131.48, 131.31, 129.84, 129.54, 127.16, 125.90, 122.35, 122.29, 121.34, 120.70, 114.81, 111.00. HRMS (ESI) calcd for C20H13ClN3 [M+H] 330.0793, found 330.0786.
9-Benzyl-9H-pyrido[3,4-b]indole 2-oxide (6ab): Yellow solid, 22.7 mg, 83% yield. m.p. 75~77 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.47 (s, 1H), 8.16 (d, J=6.6 Hz, 1H), 8.07 (d, J=7.9 Hz, 1H), 7.89 (d, J=6.6 Hz, 1H), 7.56 (t, J=7.4 Hz, 1H), 7.47 (d, J=8.3 Hz, 1H), 7.35 (t, J=7.5 Hz, 1H), 7.29 (d, J=7.1 Hz, 3H), 7.15 (dd, J=8.3, 6.0 Hz, 2H), 5.44 (s, 2H); 13C NMR (126 MHz, CDCl3) δ: 142.65, 137.73, 135.26, 131.61, 129.16, 128.32, 128.27, 126.49, 122.85, 121.56, 121.29, 121.19, 121.07, 116.28, 109.79, 47.28. HRMS (ESI) calcd for C18H15N2O [M+H] 275.1179, found 275.1181.
9-Phenethyl-9H-pyrido[3,4-b]indole 2-oxide (6ac): Yel- low solid, 23.9 mg, 83% yield. m.p. 72~76 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.36 (s, 1H), 8.11 (dd, J=6.6, 1.1 Hz, 1H), 8.02 (d, J=7.8 Hz, 1H), 7.83 (d, J=6.7 Hz, 1H), 7.53 (t, J=7.7 Hz, 1H), 7.34~7.28 (m, 2H), 7.25~7.21 (m, 3H), 7.09~7.06 (m, 2H), 4.44 (t, J=7.3 Hz, 2H), 3.12 (t, J=7.3 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ: 142.06, 137.55, 137.47, 131.21, 128.86, 128.67, 128.05, 127.17, 122.37, 121.22, 121.19, 120.96, 120.92, 116.16, 109.56, 45.63, 35.08. HRMS (ESI) calcd for C19H17N2O [M+H] 289.1336, found 289.1338.
9-(3-Phenylpropyl)-9H-pyrido[3,4-b]indole 2-oxide (6ad): Yellow solid, 21.7 mg, 72% yield. m.p. 159~182 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.48 (s, 1H), 8.14 (d, J=6.5 Hz, 1H), 8.01 (d, J=7.8 Hz, 1H), 7.83 (d, J=6.5 Hz, 1H), 7.54 (t, J=7.6 Hz, 1H), 7.33~7.28 (m, 4H), 7.22 (t, J=7.3 Hz, 1H), 7.14 (d, J=7.3 Hz, 2H), 4.22 (t, J=7.4 Hz, 2H), 2.70 (t, J=7.6 Hz, 2H), 2.12~2.16 (m, 2H); 13C NMR (126 MHz, CDCl3) δ: 142.20, 140.14, 137.45, 131.20, 128.65, 128.21, 128.07, 126.43, 122.38, 121.32, 121.23, 120.97, 120.87, 116.23, 109.60, 43.14, 33.11, 29.89. HRMS (ESI) calcd for C20H19N2O [M+H] 303.1492, found 303.1495.
4-(2-Fluorophenyl)-3-((3-phenylpropyl)amino)pyridine 1-oxide (6ad-2): White solid, 50 mg, 77%. m.p. 110~114 ℃; 1H NMR (500 MHz, CDCl3) δ: 7.72~7.71 (m, 1H), 7.68 (dd, J=6.3, 1.6 Hz, 1H), 7.45~7.40 (m, 1H), 7.30~7.14 (m, 6H), 7.10 (d, J=7.2 Hz, 2H), 6.93 (d, J=6.3 Hz, 1H), 3.78 (t, J=5.2 Hz, 1H), 3.06 (q, J=6.8 Hz, 2H), 2.63 (t, J=7.5 Hz, 2H), 1.88 (p, J=7.3 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ: 159.59 (d, J=248.5 Hz), 143.95, 140.81, 131.18 (d, J=2.7 Hz), 131.07 (d, J=8.3 Hz), 128.60, 128.33, 127.96, 126.78, 126.25, 125.18 (d, J=3.4 Hz), 123.09, 122.48 (d, J=16.0 Hz), 120.16, 116.71 (d, J=21.7 Hz), 42.84, 33.06, 30.29; 19F NMR (471 MHz, CDCl3) δ: —113.14. HRMS (ESI) calcd for C20H20FN2O [M+H] 323.1555, found 323.1567.
9-(2-(Benzo[d][1,3]dioxol-5-yl)ethyl)-9H-pyrido[3,4-b]indole 2-oxide (6ae): Yellow solid, 15.6 mg, 47% yield. m.p. 205~208 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.39 (s, 1H), 8.11 (d, J=6.6 Hz, 1H), 7.99 (t, J=13.9 Hz, 1H), 7.81 (t, J=17.2 Hz, 1H), 7.53 (t, J=7.7 Hz, 1H), 7.31 (dd, J=17.9, 8.4 Hz, 1H), 6.64 (d, J=7.8 Hz, 1H), 6.54 (s, 1H), 6.47 (d, J=7.8 Hz, 1H), 5.89 (s, 1H), 4.38 (t, J=7.2 Hz, 1H), 3.02 (t, J=7.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ: 147.97, 146.66, 142.05, 137.49, 131.26, 131.19, 128.03, 122.35, 121.70, 121.24, 121.13, 120.98, 120.92, 116.20, 109.54, 108.99, 108.59, 101.02, 45.78, 34.76. HRMS (ESI) calcd for C20H17N2O3 [M+H] 333.1234, found 333.1236.
9-(2-(Thiophen-2-yl)ethyl)-9H-pyrido[3,4-b]indole 2-oxide (6af): Yellow oil, 13.2 mg, 45% yield. 1H NMR (500 MHz, CDCl3) δ: 8.42 (s, 1H), 8.11 (d, J=6.6 Hz, 1H), 8.02 (d, J=7.9 Hz, 1H), 7.84 (d, J=6.6 Hz, 1H), 7.54 (t, J=7.7 Hz, 1H), 7.36~7.30 (m, 2H), 7.12 (d, J=5.1 Hz, 1H), 6.85~6.83 (m, 1H), 6.66 (d, J=3.2 Hz, 1H), 4.48 (t, J=7.0 Hz, 2H), 3.34 (t, J=7.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ: 142.11, 139.21, 137.58, 131.32, 128.22, 127.36, 126.24, 124.78, 122.43, 121.41, 121.32, 121.09, 121.03, 116.26, 109.56, 45.78, 41.02. HRMS (ESI) calcd for C17H15N2OS [M+H] 295.0900, found 295.0902.
9-(4,4-Diethoxybutyl)-9H-pyrido[3,4-b]indole 2-oxide (6ag): Yellow oil, 18.0 mg, 55% yield. 1H NMR (500 MHz, CDCl3) δ: 8.55 (s, 1H), 8.10 (d, J=6.5 Hz, 1H), 7.97 (d, J=7.8 Hz, 1H), 7.81 (d, J=6.6 Hz, 1H), 7.52 (t, J=7.5 Hz, 1H), 7.42 (d, J=8.3 Hz, 1H), 7.27 (t, J=7.6 Hz, 1H), 4.44 (t, J=5.4 Hz, 1H), 4.24 (t, J=7.3 Hz, 2H), 3.58 (dq, J=9.2, 7.0 Hz, 2H), 3.42 (dq, J=9.3, 7.0 Hz, 2H), 1.94~1.88 (m, 2H), 1.66~1.62 (m, 2H), 1.15 (t, J=7.1 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ: 142.28, 137.48, 131.14, 128.08, 122.45, 121.35, 121.20, 120.92, 120.82, 116.21, 109.69, 102.41, 61.63, 43.55, 30.96, 23.96, 15.30. HRMS (ESI) calcd for C19H25N2O3 [M+H] 329.1860, found 329.1864.
7-Methyl-9-(3-phenylpropyl)-9H-pyrido[3,4-b]indole 2-oxide (6bd): Yellow solid, 23.0 mg, 73% yield. m.p. 175~179 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.43 (s, 1H), 8.09 (d, J=6.5 Hz, 1H), 7.84 (d, J=8.0 Hz, 1H), 7.73 (d, J=6.6 Hz, 1H), 7.28 (t, J=7.5 Hz, 2H), 7.20 (t, J=6.3 Hz, 1H), 7.13 (d, J=7.4 Hz, 2H), 7.10 (d, J=8.0 Hz, 1H), 7.03 (s, 1H), 4.14 (t, J=7.3 Hz, 2H), 2.67 (t, J=7.5 Hz, 2H), 2.52 (s, 3H), 2.18~2.12 (m, 2H); 13C NMR (126 MHz, CDCl3) δ: 142.67, 140.21, 138.77, 137.42, 130.96, 128.61, 128.27, 126.39, 122.49, 122.21, 121.52, 120.86, 118.64, 115.78, 109.67, 42.86, 33.01, 29.80, 22.36. HRMS (ESI) calcd for C21H21N2O [M+H] 317.1649, found 317.1652.
6-Methyl-9-(3-phenylpropyl)-9H-pyrido[3,4-b]indole 2-oxide (6cd): Yellow solid, 19.2 mg, 61% yield. m.p. 175~179 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.46 (s, 1H), 8.11 (d, J=6.6 Hz, 1H), 7.80 (s, 2H), 7.36 (d, J=8.4 Hz, 1H), 7.30 (t, J=7.5 Hz, 2H), 7.22 (t, J=6.4 Hz, 2H), 7.14 (d, J=7.5 Hz, 2H), 4.20 (t, J=7.3 Hz, 2H), 2.69 (t, J=7.6 Hz, 2H), 2.53 (s, 3H), 2.21~2.15 (m, 2H); 13C NMR (126 MHz, CDCl3) δ: 140.56, 140.21, 137.56, 130.91, 130.46, 129.54, 128.63, 128.22, 126.40, 122.30, 121.15, 121.09, 120.99, 116.10, 109.31, 43.16, 33.12, 29.94, 21.31. HRMS (ESI) calcd for C21H21N2O [M+H] 317.1649, found 317.1652.
6-Cyano-9-(3-phenylpropyl)-9H-pyrido[3,4-b]indole 2-oxide (6dd): White solid, 23.2 mg, 71% yield. m.p. 228~230 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.56 (s, 1H), 8.33 (s, 1H), 8.20 (d, J=6.7 Hz, 1H), 7.89 (d, J=6.7 Hz, 1H), 7.75 (dd, J=8.6, 1.3 Hz, 1H), 7.36 (d, J=8.6 Hz, 1H), 7.29 (t, J=7.4 Hz, 2H), 7.22 (d, J=7.3 Hz, 1H), 7.13 (d, J=7.2 Hz, 2H), 4.28 (t, J=7.4 Hz, 2H), 2.73 (dd, J=16.1, 8.7 Hz, 2H), 2.26~2.20 (m, 2H); 13C NMR (126 MHz, CDCl3) δ: 143.69, 139.67, 138.39, 132.78, 130.73, 128.75, 128.17, 126.63, 126.09, 123.10, 121.32, 119.70, 119.44, 116.82, 110.49, 104.08, 43.42, 32.94, 29.72. HRMS (ESI) calcd for C21H18N3O [M+H] 328.1445, found 328.1447.

4.2.2 Synthetic transformation

To a round-bottom flask equipped with a magnetic stir bar, tert-butyl 4-(6-(6-bromo-3-chloro-9H-pyrido[3,4-b] indol-9-yl) pyridin-3-yl)piperazine-1-carboxylate (3ia) (0.0542 g, 0.1 mol), phenylboronic acid (0.0146 g, 0.12 mmol), Pd(PPh3)4 (0.0112 g, 0.01 mmol), and Na2CO3 (0.0640 g, 0.6mmol) were added. After the flask was evacuated and back-filled with argon (this process was repeated a total of three times), a mixture of solvent, toluene (6 mL), ethanol (4 mL), and water (2 mL) were added to the flask, and the mixture was stirred at 100 ℃ in an oil bath for 24 h. After completion of the reaction, the reaction mixture was extracted with EtOAc (15 mL×3). The organic layer was washed with brine and dried over Na2SO4. The filtrate was concentrated in vacuo and purified by silica gel column chromatography with hexane/EtOAc as an eluent. tert-Butyl 4-(6-(3-chloro-6-phenyl-9H-pyrido- [3,4-b]indol-9-yl) pyridin-3-yl)piperazine-1-carboxylate
(3ia-1) was obtained as a brown solid in 89% yield (0.0482 g). m.p. 94~95 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.87 (d, J=0.9 Hz, 1H), 8.33 (d, J=3.0 Hz, 1H), 8.25 (d, J=1.7 Hz, 1H), 7.96 (d, J=0.9 Hz, 1H), 7.79~7.74 (m, 2H), 7.65~7.62 (m, 2H), 7.48~7.39 (m, 4H), 7.37~7.34 (m, 1H), 3.65 (t, J=5.1 Hz, 4H), 3.27 (t, J=5.1 Hz, 4H), 1.51 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.63, 145.69, 142.19, 141.40, 140.88, 140.70, 137.65, 135.69, 134.80, 133.38, 132.80, 128.99, 128.94, 127.21, 127.12, 125.39, 121.61, 120.06, 118.84, 114.39, 111.93, 80.27, 48.49, 42.99, 28.46. HRMS (ESI) calcd for C31H31ClN5O2 [M+H] 540.2161, found 540.2169.
To a round-bottom flask equipped with a magnetic stir bar, tert-butyl 4-(6-(6-bromo-3-chloro-9H-pyrido[3,4-b] indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ia) (0.0271 g, 0.05 mmol), 1-ethynyl-4-methoxybenzene (10 μL, 0.07 mmol), Pd(PPh3)4 (0.0023 g, 0.002 mmol), and CuI (0.0008 g, 0.003 mmol) were added. After the flask was evacuated and back-filled with argon (this process was repeated a total of three times), a mixture of solvent, N,N-dimethylformamide (0.6 mL), and triethylamine (0.6 mL) were added to the flask, and the mixture was stirred at 120 ℃ in an oil bath for 24 h. After completion of the reaction, the reaction mixture was extracted with EtOAc (10 mL×3). The organic layer was washed with brine and dried over Na2SO4. The filtrate was concentrated in vacuo and purified by silica gel column chromatography with hexane/EtOAc as an eluent. tert-Butyl 4-(6-(3-chloro-6- ((4-methoxyphenyl)ethynyl)-9H-pyrido[3,4-b]indol-9-yl)pyridin-3-yl)piperazine-1-carboxylate (3ia-2) was obtained as a brown solid in 75% yield (22 mg). m.p. 122~124 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.87 (s, 1H), 8.37 (d, J=2.8 Hz, 1H), 8.28 (s, 1H), 7.97 (s, 1H), 7.73~7.67 (m, 2H), 7.54~7.45 (m, 4H), 6.93~6.89 (m, 2H), 3.86 (s, 3H), 3.68 (t, J=5.1 Hz, 4H), 3.31 (t, J=5.2 Hz, 4H), 1.53 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 159.62, 154.62, 145.89, 141.87, 141.71, 140.67, 137.73, 135.72, 133.41, 133.01, 132.76, 132.29, 125.35, 125.08, 121.16, 119.09, 116.63, 115.41, 114.49, 114.08, 111.72, 88.87, 88.11, 80.31, 55.34, 48.46, 43.47, 28.44. HRMS (ESI) calcd for C34H33ClN5O3 [M+H] 594.2267, found 594.2274.
To a round-bottom flask equipped with a magnetic stir bar, tert-butyl 4-(6-(6-bromo-3-chloro-9H-pyrido[3,4-b] indol-9-yl) pyridin-3-yl)piperazine-1-carboxylate (3ia) (0.0271 g, 0.05 mmol), aniline (7 μL, 0.075 mmol), Pd(t-Bu3P)2 (0.0010 g, 0.002 mmol), and t-BuONa (0.0106 g, 0.11 mmol) were added. After the flask was evacuated and back-filled with argon (this process was repeated a total of three times), toluene (1.2 mL) was added to the flask, and the mixture was stirred at 114 ℃ in an oil bath for 24 h. After completion of the reaction, the reaction mixture was extracted with EtOAc (10 mL×3). The organic layer was washed with brine and dried over Na2SO4. The filtrate was concentrated in vacuo and purified by silica gel column chromatography with hexane/EtOAc as an eluent. tert-Butyl 4-(6-(3-chloro-6-(phenylamino)-9H-pyrido[3,4-b]indol-9-yl)pyridin-3-yl)piperazine-1-carboxy-late (3ia-3) was obtained as a brown solid in 49% yield (0.0136 g). m.p. 109~110 ℃; 1H NMR (500 MHz, CDCl3) δ: 8.90 (s, 1H), 8.38 (s, 1H), 7.89 (d, J=10.8 Hz, 1H), 7.85 (s, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.52~7.47 (m, 2H), 7.39 (d, J=8.1 Hz, 1H), 7.30 (d, J=7.7 Hz, 2H), 7.06 (d, J=6.6 Hz, 2H), 6.94 (s, 1H), 3.69 (t, J=5.2 Hz, 4H), 3.32 (t, J=7.7 Hz, 4H), 1.53 (s, 9H); 13C NMR (126 MHz, CDCl3) δ: 154.64, 145.64, 144.53, 142.52, 140.91, 137.80, 137.42, 137.30, 135.67, 133.23, 132.47, 129.51, 125.61, 123.90, 121.91, 120.47, 118.79, 116.48, 114.45, 112.63, 111.79, 80.31, 48.65, 42.95, 28.45. HRMS (ESI) calcd for C31H32ClN6O2 [M+H] 555.2270, found 555.2278.
Supporting Information Experimental procedures, the synthesis method of the starting materials, and compound characterization data, X-ray data for compound 3ca. The Supporting Information is available free of charge via the Internet at http://sioc-journal.cn/.
(Lu, Y.)
[1]
Abramovitch, R. A.; Spenser, I. D. Adv. Heterocycl. Chem. 1964, 3, 79.

PMID

[2]
(a) Cao, R.; Peng, W.; Wang, Z.; Xu, A. Curr. Med. Chem. 2007, 14, 479.

(b) Alekseyev, R. S.; Kurkin, A. V.; Yurovskaya, M. A. Chem. Heterocycl. Compd. 2009, 45, 889.

(c) Smith, K. L.; Ford, G. K.; Jessop, D. S.; Finn, D. P. J. Psychopharmacol. 2013, 27, 162.

(d) Riyazahmed, K. S.; Bora, D.; Shankaraiah, N. Asian J. Org. Chem. 2021, 10, 1050.

DOI

(e) Olajide, O. A.; Heiss, E. H.; Schachner, D.; Wright, C. W.; Vollmar, A. M.; Dirsch, V. M. Bioorg. Med. Chem. 2007, 15, 43.

(f) Löscher, W.; Schneider, H.; Kehr, W. Eur. J. Pharmacol. 1985, 114, 261.

PMID

(g) Chen, J.; Dong, X.; Liu, T.; Lou, J.; Jiang, C.; Huang, W.; He, Q.; Yang, B.; Hu, Y. Bioorg. Med. Chem. 2009, 17, 3324.

(h) Sako, K.; Aoyama, H.; Sato, S.; Hashimoto, Y.; Baba, M. Bioorg. Med. Chem. 2008, 16, 3780.

(i) Cimanga, K.; De Bruyne, T.; Lasure, A.; Van Poel, B.; Pieters, L.; Claeys, M.; Berghe, D. V.; Kambu, K.; Tona, L.; Vlietinck, A. J. Planta Med. 1996, 62, 22.

PMID

(j) Ivachtchenko, A. V.; Frolov, E. B.; Mitkin, O. D.; Kysil, V. M.; Khvat, A. V.; Okun, I. M.; Tkachenko, S. E. Bioorg. Med. Chem. Lett. 2009, 19, 3183.

DOI PMID

(k) Lu, C. M.; Chen, Y. L.; Chen, H. L.; Chen, C. A.; Lu, P. J.; Yang, C. N.; Tzeng, C. C. Bioorg. Med. Chem. 2010, 18, 1948.

(l) Van Baelen, G.; Hostyn, S.; Dhooghe, L.; Tapolcsányi, P.; Mátyus, P.; Lemière, G.; Dommisse, R.; Kaiser, M.; Brun, R.; Cos, P.; Maes, L.; Hajós, G.; Riedl, Z.; Nagy, I.; Maes, B. U.; Pieters, L. Bioorg. Med. Chem. 2009, 17, 7209.

(m) Kushwaha, P.; Kumar, V.; Saha, B. Eur. J. Med. Chem. 2023, 252, 115247.

(n) Wang, S.; Wang, Y.; Liu, W.; Liu, N.; Zhang, Y.; Dong, G.; Liu, Y.; Li, Z.; He, X.; Miao, Z.; Yao, J.; Li, J.; Zhang, W.; Sheng, C. ACS Med. Chem. Lett. 2014, 5, 506.

(o) Dai, J. K.; Dan, W. J.; Wan, J. B. Eur. J. Med. Chem. 2022, 229, 114057.

[3]
Helbecque, N.; Moquin, C.; Bernier, J. L.; Morel, E.; Guyot, M.; Henichart, J. P. Cancer Biochem. Biophys. 1987, 9, 271.

PMID

[4]
(a) Shin-Ya, K.; Kim, J. S.; Furihata, K.; Hayakawa, Y.; Seto, H. J. Asian Nat. Prod. Res. 2000, 2, 121.

PMID

(b) Kim, J.-S.; Shin-ya, K.; Furihata, K.; Hayakawa, Y.; Seto, H. Tetrahedron Lett. 1997, 38, 3431.

[5]
(a) Perkin, W. H.; Robinson, R. J. Chem. Soc., Trans. 1912, 101, 1775.

(b) Poindexter, E. H.; Carpenter, R. D. Phytochemistry 1962, 1, 215.

[6]
Ahmad, A.; Khan, K. A.; Sultana, S.; Siddiqui, B. S.; Begum, S.; Faizi, S.; Siddiqui, S. J. Ethnopharmacol. 1992, 35, 289.

DOI PMID

[7]
Hamsa, T. P.; Kuttan, G. Chin. Med. 2011, 6, 11.

[8]
Marinović, M.; Poje, G.; Perković, I.; Fontinha, D.; Prudêncio, M.; Held, J.; Pessanha de Carvalho, L.; Tandarić, T.; Vianello, R.; Rajić, Z. Eur. J. Med. Chem. 2021, 224.

[9]
Zetler, G.; Back, G.; Iven, H. Naunyn. Schmiedebergs Arch. Pharmacol. 1974, 285, 273.

[10]
Shi, C. C.; Chen, S. Y.; Wang, G. J.; Liao, J. F.; Chen, C. F. Eur. J. Pharmacol. 2000, 390, 319.

PMID

[11]
Aufdembrinke, B. Br. J. Psychiatry Suppl. 1998,55.

[12]
Turski, L.; Stephens, D. N.; Jensen, L. H.; Petersen, E. N.; Meldrum, B. S.; Patel, S.; Hansen, J. B.; Löscher, W.; Schneider, H. H.; Schmiechen, R. J. Pharmacol. Exp. Ther. 1990, 253, 344.

PMID

[13]
Ibrahim, S. R.; Mohamed, G. A.; Zayed, M. F.; Sayed, H. M. Drug Res. 2015, 65, 361.

DOI PMID

[14]
Seville, S.; Phillips, R. M.; Shnyder, S. D.; Wright, C. W. Bioorg. Med. Chem. 2007, 15, 6353.

[15]
(a) Love, B. E. Org. Prep. Proced. Int. 1996, 28, 1.

(b) Movassaghi, M.; Hill, M. D. Org. Lett. 2008, 10, 3485.

DOI PMID

[16]
(a) Audia, J. E.; Droste, J. J.; Nissen, J. S.; Murdoch, G. L.; Evrard, D. A. J. Org. Chem. 1996, 61, 7937.

(b) Wang, L.-N.; Shen, S.-L.; Qu, J. RSC Adv. 2014, 4, 30733.

(c) Abe, T.; Yamada, K. J. Nat. Prod. 2017, 80, 241.

(d) Rao, R. N.; Maiti, B.; Chanda, K. ACS Comb. Sci. 2017, 19, 199.

[17]
(a) Ding, S.; Shi, Z.; Jiao, N. Org. Lett. 2010, 12, 1540.

(b) Tang, S.; Wang, J.; Xiong, Z.; Xie, Z.; Li, D.; Huang, J.; Zhu, Q. Org. Lett. 2017, 19, 5577.

DOI PMID

(c) Mulcahy, S. P.; Varelas, J. G. Tetrahedron Lett. 2013, 54, 6599.

(d) Dhara, S.; Singha, R.; Ahmed, A.; Mandal, H.; Ghosh, M.; Nuree, Y.; Ray, J. K. RSC Adv. 2014, 4, 45163.

(e) Yan, Q.; Gin, E.; Banwell, M. G.; Willis, A. C.; Carr, P. D. J. Org. Chem. 2017, 82, 4328.

(f) Zhu, Y.-S.; Wang, H.-Y.; Shu, P.-H.; Zhang, K.-N.; Wang, Q.-L. Chin. J. Org. Chem. 2024, 44, 204 (in Chinese).

(朱彦硕, 王红言, 舒朋华, 张克娜, 王琪琳, 有机化学, 2024, 44, 204.)

[18]
(a) Langer, P.; Dang, T. T.; Hung, T. Q.; Van Phuc, B.; Do, H. N.; Quan, N. M.; Tuan, N. N.; An, N. Q.; Van Tuyen, N.; Anh, H. L. T. Synlett 2021, 32, 1004.

(b) Hung, T. Q.; Hieu, D. T.; Van Tinh, D.; Do, H. N.; Nguyen Tien, T. A.; Van Do, D.; Son, L. T.; Tran, N. H.; Van Tuyen, N.; Tan, V. M.; Ehlers, P.; Dang, T. T.; Langer, P. Tetrahedron 2019, 75.

[19]
Chatterjee, S.; Khatun, R.; Ali, M.; Chowdhury, C. Chem. Commun. 2024, 60, 7427.

[20]
Zhu, D.; Wu, Z.; Liang, L.; Sun, Y.; Luo, B.; Huang, P.; Wen, S. RSC Adv. 2019, 9, 33170.

[21]
(a) Clarkson, G. J.; Roesner, S. J. Org. Chem. 2023, 88, 684.

(b) Sathiyalingam, S.; Roesner, S. Adv. Synth. Catal. 2022, 364, 1769.

文章导航

/